arsenic trioxide has been researched along with decitabine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S | 1 |
| Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS | 1 |
| Bartlett, DL; Gorry, MC; Guo, ZS; Li, Q; O'Malley, ME | 1 |
| Gotlib, J; Greenberg, PL | 1 |
| Jiang, J; Liu, XS; Peng, CY; Zheng, HT | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Guo, LP; Li, LW; Li, XY; Lu, SX; Yu, XY; Zhou, Y | 1 |
| Luo, JM; Sun, J; Zhang, XK | 1 |
| Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J | 1 |
| Chiu, JF; Huang, N; Li, G; Lin, W; Pei, X; Tao, T | 1 |
| Fu, R; Huang, L; Jiang, H; Li, L; Liu, Z | 1 |
| Ai, H; Chen, L; Mi, RH; Song, YP; Wang, Q; Wei, XD; Yin, QS | 1 |
| Naoe, T | 1 |
| He, J; Wang, L; Yan, X | 1 |
4 review(s) available for arsenic trioxide and decitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin | 2020 |
1 trial(s) available for arsenic trioxide and decitabine
| Article | Year |
|---|---|
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult | 2011 |
10 other study(ies) available for arsenic trioxide and decitabine
| Article | Year |
|---|---|
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides | 2007 |
Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Genes, Homeobox; Growth Inhibitors; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Male; Mice; Oxides; Pyridines; Transcription Factors; Up-Regulation | 2009 |
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Drug Antagonism; Drug Synergism; Electrophoresis, Capillary; Growth Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Leukemia; Oxides; U937 Cells; Valproic Acid | 2010 |
[Mechanism of loss of human esophageal cancer-related gene 4 (ECRG4) gene expression in esophageal squamous cell carcinoma cell line EC9706].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Esophageal Neoplasms; Exons; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Oxides; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins | 2011 |
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Janus Kinase 3; K562 Cells; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; TYK2 Kinase | 2014 |
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Bone and Bones; Bone Marrow Cells; Cell Survival; Cells, Cultured; Decitabine; Mice, Transgenic; Myelodysplastic Syndromes; Nanoparticles; Oxides; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution | 2017 |
DNA methylation of a non-CpG island promoter represses NQO1 expression in rat arsenic-transformed lung epithelial cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Transformed; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epithelial Cells; Gene Expression Regulation; Lung; NAD(P)H Dehydrogenase (Quinone); Oxides; Promoter Regions, Genetic; Rats | 2018 |
Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Topics: Acetylcysteine; Antioxidants; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation; Humans; Inhibitory Concentration 50; Myelodysplastic Syndromes; Reactive Oxygen Species | 2019 |
[The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome].
Topics: Arsenic Trioxide; Decitabine; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2019 |